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Chronic heart failure represents a major challenge in
clinical cardiology in terms of the number of patients
involved. Over the past years, the number of heart failure
patients has increased exponentially, with recent estima-
tions indicating that five million patients in the United
States have chronic heart failure, with 550,000 new patients
diagnosed annually, resulting in one million hospitaliza-
tions [1]. The diagnostic and therapeutic costs involved
with heart failure are estimated to be more than $ 29 billion
per year [1]. The major part of costs appears related to
hospitalizations for decompensated heart failure.
The main cause of heart failure is chronic coronary
artery disease. Gheorghiade and Bonow [2] pooled 13
randomized, multicenter heart failure drug trials (with more
than 20,000 patients) published in the New England Journal
of Medicine between 1986 and 1997. It was concluded that
coronary artery disease was the underlying etiology in
almost 70% of the patients, and this figure is probably
higher because many patients in the trials did not undergo
coronary angiography.
Long-term prognosis of heart failure patients remains
poor, despite advances in different therapies. Recent data
from the Framingham study demonstrated a 5-year mortal-
ity rate of 59% for men and 45% for women with heart
failure [3]. To improve survival, adequate risk stratification
is needed.
The neurohormonal system (adrenergic nervous system
and renin-angiotensin aldosteron system) plays a major role
in the pathophysiology of heart failure. One of the
characteristics is hyperactivity of the sympathetic nervous
system with an increase in plasma norepinephrine; at first,
this increased activity is supporting the cardiovascular
system by increasing heart rate, contractility, and venous
return. In chronic heart failure, however, this hyperactivity
is unfavorable and may result in desensitization and
downregulation of myocardial ß-adrenoceptor with further
impairment of cardiac performance and poor outcome.
Accordingly, assessment of the sympathetic nerve
activity and cardiac denervation may provide prognostic
information in patients with heart failure. Noninvasive
scintigraphic visualization of cardiac sympathetic nervous
system can be performed by positron emission tomography
(PET) and single photon emission computed tomography
(SPECT). The most frequently evaluated PET tracer is C11-
hydroxyephedrine (HED). In heart failure patients, global
sympathetic denervation has been demonstrated with HED
PET [4, 5]. Moreover, the reduction in HED uptake was
associated with reduced left ventricular (LV) function,
indicating a link between altered innervation and LV
function [6]. Most important, Pietila et al. [7] reported on
the prognostic value of reduced HED uptake in 46 heart
failure patients. Over a mean follow-up period of 55±
19 months, 11 cardiac deaths occurred and two underwent
heart transplantation. Multivariate analysis demonstrated
that peak oxygen uptake, LV end-diastolic volume, and
HED retention were the only predictors of outcome.
The majority of clinical innervation studies, however,
have been performed with iodine-123 metaiodobenzylgua-
nidine (MIBG) [8, 9] and planar or SPECT imaging. This
tracer is a norepinephrine analog, which is taken up and
stored in the myocardium similarly to norepinephrine [10]
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sympathetic nerve endings, providing a strong signal for
imaging. The vast majority of MIBG studies have used
planar imaging, only the more recent studies have used
SPECT imaging [8, 9]. The imaging protocol usually
includes acquisition of an early and late dataset; the early
images are obtained 10–20 min after tracer injection,
whereas the late images are obtained 3–4 h later. The
imaging parameters obtained with planar imaging include
the early and late heart-to-mediastinum (H/M) ratio and the
washout rate, and all provide information on global cardiac
sympathetic innervation and denervation. With SPECT
imaging, it is also possible to evaluate regional innervation
or denervation.
Various studies have published on the use of MIBG
imaging in relation to prognosis in heart failure patients
[8, 9]. Most of these studies employed the late H/M ratio as
prognostic marker. Merlet et al. [11] evaluated 90 patients
with ischemic and nonischemic heart failure; these patients
underwent planar MIBG imaging (images obtained 4 h after
tracer injection) in addition to routine care (chest X-ray,
echocardiography, and radionuclide LV ejection fraction
(LVEF) assessment). During a follow-up period of maxi-
mum 27 months, ten patients underwent cardiac transplan-
tation, and 22 died. Among all clinical and imaging
variables, the H/M ratio on MIBG imaging was the only
predictor of event-free survival.
T h es a m eg r o u p[ 12] subsequently evaluated 112
patients with heart failure and dilated cardiomyopathy
(NYHA class II–IV, LVEF <40%, LV end-diastolic diam-
eter 70±8 mm, and pulmonary capillary wedge pressure
19±8 mm Hg) who underwent planar MIBG imaging 4 h
after tracer injection. Among all variables, only the H/M
ratio on MIBG imaging and the LVEF were predictive for
long-term survival (mean follow-up 27±20 months). Of
note, Merlet et al. [11, 12] used a cutoff value for the H/M
ratio of 1.2 to identify reduced MIBG uptake. Cohen-Solal
and coworkers [13] evaluated 93 heart failure patients with
early and late planar MIBG imaging and demonstrated that
the reduction in H/M ratio on the delayed MIBG images was
related to LVEF, cardiac index, pulmonary wedge pressure,
and peak oxygen uptake. Moreover, the H/M ratio (cutoff
value 1.2) and peak oxygen uptake were predictive of death
or cardiac transplantation over 10±8 months follow-up.
Nakata et al. [14] evaluated 414 patients, with 173
having symptomatic heart failure; all underwent early
(10 min) and late (3–4 h) planar MIBG imaging. Over a
mean follow-up of 22±7 months, 37 cardiac deaths
occurred. Five main predictors of death were identified
including an H/M ratio on late MIBG imaging, LVEF ÿ%,
NYHA class III or IV, age >60 years and a history of
myocardial infarction. Of note, Nakata et al. [14] used a
cutoff value of 1.74 to define a reduced H/M ratio.
Wakabayashi et al. [15] compared the prognostic value
of cardiac MIBG imaging in patients with ischemic (n=76)
and nonischemic cardiomyopathy (n=56). Over a maxi-
mum period of 55 months, 69 cardiac deaths occurred. Both
in the patients with ischemic and nonischemic cardiomy-
opathy, the late H/M ratio was the strongest predictor of
survival. Importantly, the cutoff values for H/M ratios were
1.5 in ischemic patients, and 2.0 in nonischemic patients.
In addition to the late H/M ratio, the prognostic value of
other MIBG parameters has also been reported. Ogita et al.
[16] evaluated 79 heart failure patients with LVEF <40%
with planar MIBG imaging; both early (20 min) and late
(3–4 h) images were obtained. A washout rate ÿ% was a
strong predictor of survival. Yamada et al. [17]a l s o
demonstrated that washout rate (cutoff value 27%) was
the strongest predictor of survival in 65 heart failure
patients with LVEF <40%, over a mean follow-up period
of 34±19 months. Anastasiou-Nana et al. [18] evaluated 52
heart failure patients with LVEF <40%, and demonstrated
that the early H/M ratio was the best predictor for long-term
(2-year) outcome. Of note, the early H/M ratio was
obtained at 1 h after tracer injection, whereas most studies
used a 10- to 20-min interval to obtain the early images.
Only few studies performed a thorough comparison
between the different MIBG parameters to predict long-
term outcome. Wakabayashi et al. [15] demonstrated in 132
patients that the late H/M ratio provided superior prognostic
information over the early H/M ratio and the washout rate.
Cohen-Solal et al. [13] reported in 93 heart failure patients
that the late H/M ratio provided prognostic information
whereas the early H/M ratio and washout rate did not.
Although currently available data suggest that the late H/M
ratio may be the best prognostic parameter that can be
obtained from planar MIBG imaging, it is clear that further
studies are needed to solve this issue.
In addition, the optimal cutoff value for the H/M ratio on
late MIBG imaging is unclear, and various cutoff values
have been used. This is (at least partially) related to the lack
of standardization of data acquisition and data analysis.
Accordingly, larger studies are needed to obtain these
optimal cutoff values. In this perspective, the study by
Agostini et al. [19] in the current issue of the journal is a
very important contribution. In this analysis, data from 290
heart failure patients (121 ischemic and 169 nonischemic
cardiomyopathy, obtained in six European centers) who
underwent planar MIBG imaging are re-analyzed in a core
laboratory. In this core laboratory, H/M ratios were obtained
from the digitized images; only late H/M ratios were
derived because early MIBG scans were not available in
72% of patients. The late images were obtained between 2
and 7 h after tracer injection. All patients had a predefined
2-year follow-up period, and patients with less than 2-year
follow-up were excluded. Over this period, a total of 67
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including 18 cardiac deaths, 44 cardiac transplantations,
and five potentially lethal ventricular arrhythmias. The
mean H/M ratio was significantly different between patients
with and without events (1.51 versus 1.97, P<0.001).
Based on receiver operating characteristic (ROC) curve
analysis, a cutoff value for H/M ratio of 1.75 yielded a
sensitivity of 84% with a specificity of 60% to predict
events. Based on this cutoff value, the 2-year event-free
survival was 92% for patients with an H/M ratio ÿ.75 as
compared to 62% for patients with an H/M ratio <1.75 (P<
0.001). When the H/M ratios were divided into quartiles,
the 2-year event-rate in the lowest quartile (ÿ.45) was
almost 50%, as compared to 1.4% in the highest quartile
(ÿ.18). These data provide further support for the use of the
late H/M ratio for prognostic purposes in heart failure
patients,witha proposedcutoff valueof1.75forthelate H/M
ratio. Although the current study is a major step forward in
the direction of clinical use of MIBG imaging in heart
failure patients, several limitations are important. First, the
retrospective nature and the non-uniformity in data collec-
tion (different timings for acquisition of the late H/M ratio,
ranging from 2 to 7 h after tracer injection, with different
dosages of MIBG, different gamma cameras, and different
collimators) should be acknowledged. Furthermore, a
substantial percentage of patients had mild heart failure,
with 57% in NYHA class II and 34% of patients having an
LVEF >35%. It is anticipated that patients with more severe
heart failure have lower H/M ratios and the optimal cutoff
value for prediction of events will be lower than 1.75;
although a sub-analysis of patients with LVEF ÿ% is
included, an ROC curve analysis for these patients is not
presented. Despite these shortcomings, the study by
Agostini et al. [18] adds substantially to the existing
literature and provides further evidence supporting the use
of MIBG in risk stratification of heart failure patients.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which permits
any noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. American Heart Association. Heart disease and stroke statistics,
2006 update: a report from the American Heart Association
Statistics Committee and Stroke Statistics Subcommittee. Circu-
lation. 2006;113:e85–151.
2. Gheorghiade M, Bonow RO. Chronic heart failure in the United
States. A manifestation of coronary artery disease. Circulation.
1998;97:282–9.
3. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho
KK, et al. Long-term trends in the incidence of and survival with
heart failure. N Engl J Med. 2002;347:1397–402.
4. Hartmann F, Ziegler S, Nekolla S, Hadamitzky M, Seyfarth M,
Richardt G, et al. Regional patterns of myocardial sympathetic
denervation in dilated cardiomyopathy: an analysis using carbon-
11 hydroxyephedrine and positron emission tomography. Heart.
1999;81:262–70.
5. Bengel FM, Schwaiger M. Assessment of cardiac sympathetic
neuronal function using PET imaging. J Nucl Cardiol. 2004;
11:603–16.
6. Bengel FM, Permanetter B, Ungerer M, Nekolla S, Schwaiger M.
Relationship between altered sympathetic innervation, oxidative
metabolism and contractile function in the cardiomyopathic
human heart; a non-invasive study using positron emission
tomography. Eur Heart J. 2001;22:1594–600.
7. Pietila M, Malminiemi K, Ukkonen H, Saraste M, Någren K,
Lehikoinen P, et al. Reduced myocardial carbon-11 hydroxyephe-
drine retention is associated with poor prognosis in chronic heart
failure. Eur J Nucl Med. 2001;28:373–6.
8. Flotats A, Carrio I. Cardiac neurotransmission SPECT imaging. J
Nucl Cardiol. 2004;11:587–602.
9. Carrio I. Cardiac neurotransmission imaging. J Nucl Med.
2001;42:1062–76.
10. Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL,
Clinthorne NH, et al. Myocardial imaging with a radio-iodinated
norepinephrine storage analog. J Nucl Med. 1981;22:22–31.
11. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove
P, et al. Prognostic value of cardiac metaiodobenzylguanidine
imaging in patients with heart failure. J Nucl Med. 1992;33:
471–7.
12. Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL,
Duval AM, et al. Prognostic value of MIBG imaging in idiopathic
dilated cardiomyopathy. J Nucl Med. 1999;40:917–23.
13. Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C,
Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in
patients with moderate chronic heart failure: relationship with peak
oxygen uptake and prognosis. J Am Coll Cardiol. 1999;33:759–
66.
14. Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T,
Kobayashi H, et al. Cardiac death prediction and impaired
c a r d i a cs y m p a t h e t i ci n n e r v a t i o na s s e s s e db yM I B Gi np a t i e n t s
with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579–
90.
15. Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K,
Travin MI, et al. Assessment of underlying etiology and cardiac
sympathetic innervation to identify patients at high risk of cardiac
events. J Nucl Med. 2001;42:1757–67.
16. Ogita H, Shimonagata T, Fukunami M, Kumagai K, Yamada T,
Asano Y, et al. Prognostic significance of cardiac (123)I
metaiodobenzylguanidine imaging for mortality and morbidity in
patients with chronic heart failure: a prospective study. Heart.
2001;86:656–60.
17. Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H,
Hirata A, et al. Comparison of the prognostic value of cardiac
iodine-123 metaiodobenzylguanidine imaging and heart rate
variability in patients with chronic heart failure: a prospective
study. J Am Coll Cardiol. 2003;41:231–8.
18. Anastasiou-Nana MI, Terrovitis JV, Athanasoulis T, Karaloizos L,
Geramoutsos A, Pappa L, et al. Prognostic value of iodine-123-
metaiodobenzylguanidine myocardial uptake and heart rate vari-
ability in chronic congestive heart failure secondary to ischemic
or idiopathic dilated cardiomyopathy. Am J Cardiol. 2005;
96:427–31.
19. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P,
Sambuceti G, et al. I-123-mIBG myocardial imaging for assess-
ment of risk for a major cardiac event in heart failure patients:
insights from a retrospective European multi-center study. Eur J
Nucl Med Mol Imaging. 2007. DOI 10.1007/s00259-007-0639-3.
534 Eur J Nucl Med Mol Imaging (2008) 35:532–534